EyePoint Pharmaceuticals, Inc. has announced a public offering of 12,727,273 shares of its common stock at a price of $11.00 per share. The offering is expected to generate approximately $140 million in gross proceeds before underwriting discounts and commissions and other offering expenses. The company has also granted underwriters a 30-day option to purchase up to an additional 1,909,090 shares. The proceeds are intended for clinical development of DURAVYU™ for wet AMD and DME, support for earlier stage pipeline initiatives, and general corporate purposes. The shares are listed on The Nasdaq Global Market under the symbol 'EYPT.' The offering is expected to close on or about October 31, 2024, with J.P. Morgan, Citigroup, and Guggenheim Securities acting as joint book-running managers.

EyePoint Pharmaceuticals, Inc. has announced a public offering of 12,727,273 shares of its common stock at a price of $11.00 per share. The offering is expected to generate approximately $140 million in gross proceeds before underwriting discounts and commissions and other offering expenses. The company has also granted underwriters a 30-day option to purchase up to an additional 1,909,090 shares. The proceeds are intended for clinical development of DURAVYU™ for wet AMD and DME, support for earlier stage pipeline initiatives, and general corporate purposes. The shares are listed on The Nasdaq Global Market under the symbol 'EYPT.' The offering is expected to close on or about October 31, 2024, with J.P. Morgan, Citigroup, and Guggenheim Securities acting as joint book-running managers.